GH Research (GHRS) Free Cash Flow (2020 - 2025)
GH Research's (GHRS) quarterly Free Cash Flow came in at -$12.3 million in Q4 2025, down 18.14% year-on-year from -$15.0 million in Q4 2024, and up 9.76% quarter-over-quarter from -$13.6 million in Q3 2025.
GH Research (GHRS) Free Cash Flow (2020 - 2025) Analysis & Trends
GH Research's Free Cash Flow history runs 6 years deep, the most recent figure standing at -$12.3 million for Q4 2025.
- On a quarterly basis, Free Cash Flow fell 18.14% year-over-year to -$12.3 million in Q4 2025; TTM through Dec 2025 was -$43.4 million, a 2.83% decrease from a year earlier, with the FY2025 full-year figure at -$43.4 million, down 2.83% from the prior year.
- Free Cash Flow rose to -$12.3 million in Q4 2025 per GHRS's latest filing, from -$13.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$1.1 million in Q1 2021 and bottomed at -$13.6 million in Q3 2025.
- The 5-year median for Free Cash Flow is -$8.7 million (2025), against an average of -$8.2 million.
- Across the five-year window, Free Cash Flow tumbled 11800.0% in 2021 and advanced 12.4% in 2024, its largest moves.
- Year by year, Free Cash Flow stood at -$3.9 million in 2021, then plunged by 77.32% to -$7.0 million in 2022, then slumped by 70.36% to -$11.9 million in 2023, then increased by 12.4% to -$10.4 million in 2024, then fell by 18.14% to -$12.3 million in 2025.
- Per Business Quant, the three latest GHRS Free Cash Flow figures stand at -$12.3 million (Q4 2025), -$13.6 million (Q3 2025), and -$8.9 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | GH Research | 1.65 Bn | 1.65 Bn | - | -12.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.31 Mn |
| Dec 31, 2025 | -12.31 Mn |
| Sep 30, 2025 | -13.64 Mn |
| Sep 30, 2025 | -13.64 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Dec 31, 2024 | -10.42 Mn |
| Dec 31, 2024 | -10.42 Mn |
| Sep 30, 2024 | -12.30 Mn |
| Sep 30, 2024 | -12.30 Mn |
| Jun 30, 2024 | -9.93 Mn |
| Jun 30, 2024 | -9.93 Mn |
| Mar 31, 2024 | -9.58 Mn |
| Mar 31, 2024 | -9.58 Mn |
| Dec 31, 2023 | -11.90 Mn |
| Dec 31, 2023 | -11.90 Mn |
| Sep 30, 2023 | -10.33 Mn |
| Sep 30, 2023 | -10.33 Mn |